Dogwood Therapeutics, Inc.
NASDAQ:DWTXBiotechnology
+$0.04 today
- Market cap
- $51.12M
- Beta
- 1.76
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$0.84
Volume 0.12M
Average 0.09M
DWTX Goodwill
The premium paid for acquisitions above the fair value of the identifiable net assets acquired.
Dogwood Therapeutics, Inc.NASDAQ: DWTX
Goodwill · Q1 FY2026 · quarter ended Mar 2026
Goodwill remains negative
Q1 FY2026 goodwill was $12.19M, compared with $0 a year earlier.
Context
- Goodwill amounted to 12.8% of total assets at the end of Q1 FY2026, up 12.8 pp from a year earlier.
- Goodwill increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Goodwill history
USD · from the balance sheet
- Latest · FY2025
- 12.4M USD
- Year-over-year change
- +5.0%
| Period | Period end | Goodwill | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.4M | +5.0% |
| FY2024 | 2024-12-31 | 11.81M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Goodwill vs competitors
How DWTX compares with its peers on the latest reported figures
- DWTX's Mar 2026 goodwill of $12.19M is the highest of the 2 companies compared; the peer median is $0.
- Goodwill amounts to 12.8% of total assets for DWTX, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $12.19M | — | — | 12.8% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding DWTX) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for DWTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 14.01M | 7.03M | 3.32M | 14.85M | 6.52M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 863 | 7.29K | 3.56K | 28.01K | 4.88K |
| Total Current Assets | 15.78M | 8.37M | 4.17M | 16.54M | 8.43M |
| Property, Plant & Equipment (Net) | 0 | 0 | 0 | 222.65K | 194.93K |
| Goodwill | 0 | 0 | 0 | 11.81M | 12.4M |
| Intangible Assets | 0 | 0 | 0 | 65.71M | 68.99M |
| Long-term Investments | 0 | 0 | 0 | 18.13K | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 158.96K |
| Total Non-current Assets | 0 | 0 | 0 | 77.76M | 81.74M |
| Total Assets | 15.78M | 8.37M | 4.17M | 94.31M | 90.17M |
| Account Payables | 353.86K | 573.16K | 111.91K | 1.23M | 760.95K |
| Short-term Debt | 0 | 0 | 0 | 49.7K | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 532.68K | 159.7K | 0 | 687.59K | 745.08K |
| Total Current Liabilities | 1.28M | 1.04M | 358.55K | 3.18M | 3.06M |
| Long-term Debt | 0 | 0 | 0 | 15.38M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 11.31M | 12.11M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 0 | 0 | 26.85M | 12.22M |
| Total Liabilities | 1.28M | 1.04M | 358.55K | 30.03M | 15.27M |
| Common Stock | 833 | 1.83K | 77 | 133 | 2.97K |
| Retained Earnings | (43.93M) | (56.17M) | (61.47M) | (73.82M) | (108.08M) |
| Accumulated OCI | 0 | 0 | 0 | (3.86M) | (587.04K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 14.5M | 7.33M | 3.81M | 64.28M | 74.9M |
| Total Debt | 0 | 0 | 0 | 15.59M | 162.6K |
| Net Debt | (14.01M) | (7.03M) | (3.32M) | 737.71K | (6.36M) |
Dogwood Therapeutics, Inc.
NASDAQ:DWTX
Intrinsic Alpha fair value
Locked
Current Price
$1.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.